Vertex to Lay off 15% Due to Plunging Hep C Drug Sales

Despite the initial success of Vertex Pharmaceuticals' hepatitis C treatment, Incivek, in 2011, competition from all-oral hepatitis C treatments has damaged sales.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news